Stemline Therapeutics Inc

Stemline Therapeutics — Analyst and Investor Meeting, ASH 2017

41 slides from Stemline Therapeutics's conference presentation, Dec 13, 2017

  1. Slide 1: Forward-Looking Statements

    Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “potentially,” “estimates,” “antic

  2. Slide 2: Agenda

    Agenda Introduction & Next Steps 5 mins CEO, Stemline Andrew Lane, MD, PhD 3 Ivan Bergstein, MD Naveen Pemmaraju, MD Assistant Professor The University of Texas MD Anderson Cancer Center SL-401 Pivotal BPDCN Trial Results15 mins Assistant Professor Harvard Medical School/Dana-Farber Cancer Institute

  3. Slide 3: SL-401: Introduction & Next Steps

    SL-401: Introduction & Next Steps

  4. Slide 4: Stemline Clinical Pipeline

    Stemline Clinical Pipeline completed1 (CMML and MF) (in CR, MRD+) (CD123) Enrolling Myeloma (r/r) pomalidomide + dex Enrolling (IST) Elderly AML azacitidine solid tumors GBM SL-701 SL-701 single agent and + bevacizumab Completed EphA2 Survivin BPDCN = blastic plasmacytoid dendritic cell neoplasm; MP

  5. Slide 5: SL-401: Regulatory and Commercial Timeline

    SL-401: Regulatory and Commercial Timeline Submission Approval Pre-MAA EMA meeting Potential MAA Submission EU Commercial US Launch 6 4Q17 Regulatory 1Q18 2Q18 3Q18 4Q18 Complete BLA Potential 1Q19 2019 2018 2017

  6. Slide 6: SL-401: Pivotal Trial Results (ASH '17)

    SL-401: Pivotal Trial Results (ASH ‘17) #1298 Naveen Pemmaraju1, Kendra L. Sweet2, Andrew A. Lane3, Anthony S. Stein4, Sumithira Vasu5, William Blum5, David A. Rizzieri6, Eunice S. Wang7, Madeleine Duvic1, Danielle Shubert8, Sharon Spence8, Shay Shemesh8, Janice Chen8, Background and Highlights St •

  7. Slide 7: BPDCN Overview

    BPDCN Overview BPDCN Skin Lesions • • Highly aggressive hematologic malignancy Poor prognosis; median overall survival (OS) 8-14 months • Named “BPDCN” by WHO in 2008 - Derived from plasmacytoid dendritic cell (pDC) • Previous names (prior to 2008) included: - - Blastic NK cell leukemia/lymphoma Agr

  8. Slide 8: Study Design and Inclusion / Exclusion

    Study Design and Inclusion / Exclusion • • BPDCN (1L and R/R) SL-401 (12 µg/kg) via IV infusion, days 1-5 of a 21-day cycle Key objectives: further define safety and efficacy • • BPDCN (1L) SL-401 (12 µg/kg) via IV infusion, days 1-5 of a 21-day cycle Key objectives: efficacy confirmation for regist

  9. Slide 9: Demographics

    Demographics Demographics Stages 1 & 2 Stage 3 Stages 1, 2 & 3 n 32 13 45 Age, years median [range] 72 [28-84] 65 [22-84] 70 [22-84] Gender, Male [n, (%)] 26 (81) 11 (85) 37 (82) First-line (1L) [n, (%)] 19 (59) 13 (100) 32 (71) Relapsed / Refractory (R/R) [n, (%)] 13 (41) -- 13 (29) Baseline sites

  10. Slide 10: Safety and Tolerability

    Safety and Tolerability BPDCN (12 µg/kg/day); Stages 1, 2, and 3 (n=42 patients) Preferred Term Alanine aminotransferase increased Aspartate aminotransferase increased Hypoalbuminaemia ThrombocytopeniaЖ Chills Pyrexia Weight increased Nausea Capillary leak syndrome (CLS)ђ Fatigue Decreased appetite

  11. Slide 11: Clinical Activity Stage 3: BPDCN

    Clinical Activity Stage 3: BPDCN (12 µg/kg/day) (n=13 patients) Stage 3 was designed to serve as the pivotal, confirmatory cohort for the SL-401 trial in BPDCN Stage 3 met its primary endpoint with a 54% rate of CR + CRc (7/13) [95% CI: 25.1, 80.8] • • - The lower bound of the 95% CI exceeded the pr

  12. Slide 12: Clinical Activity Stages 1, 2, and 3: BPDCN

    Clinical Activity Stages 1, 2, and Stages 1, 2, and 3 respondersɸ,ɣ 3: BPDCN (12 µg/kg/day) (n=42 patients) n ORR, n (%) CR + CRc + CRi, n (%) CR CRc CRi PR, n (%) Bridged to SCT, n (%) Allo Auto 29 26 (90%) 21 (72%) 12 7 2 5 (17%) 13 (45%) 10 3 13 9 (69%) 5 (38%) 1 3 1 4 (31%) 1 (8%) 1 0 42 35 (83%

  13. Slide 13: Clinical Activity: First-line BPDCN

    Clinical Activity Stages 1 and 2: First-line BPDCN (12 µg/kg/day) Stage 3: First-line BPDCN (12 µg/kg/day) 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 Allo Allo Allo Allo Allo Allo SL-401 Stem cell transplant (SCT) Exited study in remission ¥ 0 5 10 15 20 25 30 0 2 4 6 8 10 As of September 25, 2017. Inve

  14. Slide 14: Overall Survival (OS) First-line BPDCN

    Overall Survival (OS) First-line BPDCN (12 µg/kg/day) Overall Survival Overall Survival 1L SBPtaDgCeN,3N=13 S1tLaBgPeD1CNa,nNd=126 O(SSta(gfero1-m2, 1f2irusgt/kdgo/dsaey)) (Stage 3, 12 ug/kg/day) OS (from first dose) 1.00 1.00 0.75 0.75 0.50 0.50 0.25 0.25 0.00 0.00 0 5 10 15 20 25 30 0 2 4 6 8 10 T

  15. Slide 15: Conclusions and Next Steps

    Conclusions and Next Steps • Stage 3 pivotal cohort (first-line, 12 µg/kg/day) met its primary endpoint - 54% (7/13) CR + CRc rate (95% CI: 25.1, 80.8) The lower bound of the 95% CI exceeded the pre-specified rate of 10% o - 77% (10/13) ORR; 46% (6/13) bridged to SCT • Stages 1, 2, and 3 (12 µg/kg/d

  16. Slide 16: Acknowledgements

    Acknowledgements We would like to thank: • Investigators, co-investigators, and study teams at each participating center: • This study is sponsored by Stemline Therapeutics, Inc. 18 18

  17. Slide 17: SL-401: Regulatory and Commercial Timeline

    SL-401: Regulatory and Commercial Timeline Submission Approval Pre-MAA EMA meeting Potential MAA Submission EU Commercial US Launch 19 4Q17 Regulatory 1Q18 2Q18 3Q18 4Q18 Complete BLA Potential 1Q19 2019 2018 2017

  18. Slide 18: Market Opportunity – BPDCN Universe

    Market Opportunity – BPDCN Universe Trial BPDCN clinical trial sites Centers 2 CT Centers BPDCN (US) TIER 1 Centers Trial BPDCN clinical trial sites Centers 2 CT Centers 12 Tier 1 Centers 5 Tier 2 Centers 1 Tier 3 Center 1 Hospital System Maintenance Therapy (post-SCT) ~40% first-line BPDCN patients

  19. Slide 19: Market Opportunity – BPDCN Universe

    Market Opportunity – BPDCN Universe NPM-1 mutated AML Subset “BPDCN Signature” • NPM-1 mutated AML comprises ~30% of de novo AML “...we found that a peculiar immunophenotype CD56/CD123/CD4(+)… significantly associated with worse disease free survival (p <0.01).” • A BPDCN-like signature identified i

  20. Slide 20: Pricing Landscape

    Pricing Landscape Product/Annual Treatment Cost FDA Approved Indication(s) Atrophy Uremic Syndrome US Patient Population aHUS: ~650-1,800 28,700 – 86,000 20,000-30,000 Relapsing sALCL: 3,400 – 5,100 Approved Oct, 2017 Announced “outcomes-based approach” with CMS PNH: ~5,000 ~6,000 ~7,000 Thyroid Can

  21. Slide 21: BPDCN diagnostic marker triad awareness

    B Blastic P D C N The signature marker triad co123, co4, co56 may change diagnosis-for good Neoplasm Cell COMMON MISDIAGNOSES .. ACTUALLY BE • ALL • AML • MDS • NHL • CMML BPDCN? • Leukemia cutis,cutaneous lymphoma,NK cell neoplasms · Marker CD123 CD4 CD56 TCL1 C043 Knowing can be as simple as co123

  22. Slide 22: Commercial Progress Towards U.S. Launch

    Commercial Progress Towards U.S. Launch (Key Items) 24 Pricing, Access, Reimbursement (U.S. & E.U) Payer Value Proposition & Messaging Strategy Development✅ Pricing Assessment✅ Reimbursement Assessment✅ U.S. Market Access Strategy & Operational Plan✅ Patient Engagement, Adherence, & Affordability Mo

  23. Slide 23: SL-401: Additional Opportunities

    SL-401: Additional Opportunities

  24. Slide 24: SL-401: Additional Opportunities

    SL-401: Additional Opportunities • • SL-401 across multiple indications Both single agent and in combination; various administration schedules Pomalidomide* Azacytidine* (3 days every 3-4 wks) (5 days every 4 wks) schedule TBD schedule TBD • CR rate • CR rate • DFS • ORR *Preclinical data support co

  25. Slide 25: SL-401: Additional Opportunities

    SL-401: Additional Opportunities • • SL-401 across multiple indications Both single agent and in combination; various administration schedules Azacytidine* (5 days every 4 wks) schedule TBD • DFS • ORR *Preclinical data support combination (synergy or potentiation) 27 chemo Regimen Lead-in (Stage 1)

  26. Slide 26: SL-401 MPN Phase 1/2 Trial

    SL-401 MPN Phase 1/2 Trial Median [range] 69 [43 – 81] • • MPN: CMML, MF, SM, and PED SL-401 (7, 9, or 12 µg/kg) via IV infusion, days 1-3 of a 21-day cycle (cycles 1-4), a 28-day cycle (cycles 5-7); a 42-day cycle thereafter Key objectives: determine optimal dose and regimen for Stage 2 Male 13 (54

  27. Slide 27: SL-401 MPN Trial: Best Spleen Response

    SL-401 MPN Trial: Best Spleen Response Best Percent Patient Received Histology Best Screening response Stage 1 Stage 2 Abbreviations: CR = Complete response; SD = Stable disease 29 Splenomegaly (cm palpable below left costal margin) DoseOverallTime to (µg/kg) ResponseResponseChange(weeks) 69CMML-1CR

  28. Slide 28: MPN: Best Response, Treatment Duration / Summary and Next Steps

    MPN: Best Response, Treatment Duration / Summary and Next Steps SL-401 Trial in MPN (CMML and MF) Safety • No DLTs or MTD identified. Most common TRAEs include hypoalbuminemia (33%), thrombocytopenia (33%), and fatigue (29%). Most common TRAEs, grade 3+, include thrombocytopenia (24%) and anemia (19

  29. Slide 29: SL-401: Combination Strategies

    SL-401: Combination Strategies

  30. Slide 30: Apoptotic priming, chemosensitization and synergy with SL-401

    Increased apoptotic priming and chemosensitization after SL-401, and upfront synergy between SL-401 and chemotherapy Increased apoptotic priming Increased chemosensitivity Synergy SL-401 + chemo CI=0.15 BH3 profiling after SL-401 CI=0.14 CI=0.31 Priming CI=0.27 CI=0.39

  31. Slide 31: SL-401 resistant cells internalize SL-401 but are resistant to DT

    SL-401 resistant cells internalize SL-401 but are resistant to DT CAL1 - Parental CAL1 – Resistant Red: SL-401-APC; Green: CFSE (intracellular); Blue – Hoechst (nucleus)

  32. Slide 32: Loss of DPH1 is sufficient to confer resistance to SL-401

    Loss of DPH1 is sufficient to confer resistance to SL-401 CRISPR targeting DPH1 biotin-NAD+ +/-SL-401 Cell lysate + +/-+ IL-3 DPH1 Actin No drug SL-401 1 0 0 THP1 R1 R2 R3 THP1 R1 R2 R3 N T G 1 8 0 N T G 2 ADP-R-(eEF2) g 2 6 0 g 3 eEF2 4 0 g 5 g 6 2 0 DPH1 0 0 2 4 D a y s p o s t S L - 4 0 1 6 8 Act

  33. Slide 33: SL-401 resistance associated with hypermethylation of DPH1 promoter

    SL-401 resistance assoc. with hypermethylation of DPH1 promoter CpG DNA 1 0 0 D P H 1 THP1 THP1 SL-401res - 1 P < 0 . 0 0 0 1 P = 0 . 0 0 0 3 1 . 0 THP1 SL-401res - 2 0 . 8 5 0 0 . 6 0 . 4 0 . 2 0 . 0 0 - 3 0 0 - 2 0 0 - 1 0 0 0 1 0 0 P o s i t i o n t o T S S DPH1 % m e t h y l a t e d C p G R e l

  34. Slide 34: Correction of DPH1 hypermethylation by sub-lethal azacitidine

    Correction of DPH1 hypermethylation expression by sub-lethal azacitidine 1 0 0 THP1 THP1 SL-401res - 1 THP1 SL-401res - 2 THP1 THP1 SL-401res - 1 THP1 SL-401res - 2 Vehicle 5 0 Azacitidine 0 - 3 0 0 - 2 0 0 - 1 0 0 0 1 0 0 D P H 1 P o s i t i o n t o T S S DPH1 P < 0 . 0 0 0 1 P = 0 . 0 0 0 3 1 . 0

  35. Slide 35: ADP-ribosylation activity and SL-401 sensitivity restored by azacitidine

    ADP-ribosylation activity and SL-401 sensitivity restored by azacitidine Vehicle SL-401 (repeated exposure) Cell lysate + biotin-NAD+ + SL-401 1 . 5 1 . 5 T H P 1 R 1 + + 1 . 0 IL-3 1 . 0 R 2 R 3 0 . 5 0 . 5 0 . 0 0 . 0 - 1 0 - 8 L o g [ S L - 4 0 1 ] g / m L - 6 - 1 0 - 8 L o g [ S L - 4 0 1 ] g /

  36. Slide 36: Phase 1-2 study of SL-401 plus azacitidine in AML and MDS

    Phase 1-2 study of SL-401 plus azacitidine in AML and MDS NCT03113643 • • Relapsed/refractory AML or New AML not eligible for intensive chemotherapy or MDS >10% blasts • • CD123+ blasts

  37. Slide 37: Phase 1-2 study of SL-401 plus azacitidine in AML and MDS

    Phase 1-2 study of SL-401 plus azacitidine in AML and MDS NCT03113643 * Relapsed/refractory AML * or New AML not eligible for intensive DFCI chemothera Safety Lead-In Phase 2 + or MDS 10% blasts ae ane een ~ patients) (n=24) City of Hope * CD123+ blasts Days 1-7 SL-401 n ~ > Repeat x 6+ cycles | Day

  38. Slide 38: Key Milestones and Upcoming Events

    Key Milestones and Upcoming Events Projected 40 Timing Program Expected Event 1Q17 SL-401 Completed enrollment of BPDCN pivotal trial 2Q17 SL-401 Clinical update in BPDCN at EHA 3Q17 SL-801 Phase 1 update at ESMO 2H17 SL-401 Top-line pivotal data SNO ‘17 SL-701 Patient follow-up update ASH ‘17 SL-40

  39. Slide 39: Key Milestones and Upcoming Events

    Eve Key Milestones a Expected Event Upco 1Q17 SL-401 ¥ Completed enrollment of BPDCN pivotal trial 2Q17 SL-401 Vv Clinical update in BPDCN at EHA 3Q17 SL-801 v Phase 1 update at ESMO 2H17 SL-401 Vv Top-line pivotal data SNO ‘17 SL-701 Vv Patient follow-up update ASH ‘17 SL-401 Vv Detailed pivotal da

  40. Slide 40: Stemline Therapeutics Analyst and Investor Meeting ASH 2017

    Stemline Therapeutics, Inc. NASDAQ: STML Analyst and Investor Meeting ASH 2017 December 11, 2017

  41. Slide 41: Stemline Therapeutics Analyst and Investor Meeting ASH 2017

    Sltemline Stemline Therapeutics, Inc. NASDAQ: STML Analyst and Investor Meeting ASH 2017 December 11, 2017

Stemline Therapeutics — Analyst and Investor Meeting, ASH 2017 on 6ix